Showing 7191-7200 of 10904 results for "".
Non-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.The Heritage of Platelet-Derived Growth Factor
https://practicaldermatology.com/topics/regenerative-medicine/the-heritage-of-pdgf/48868/From its discovery nearly half a century ago to its current place in patient care and scientific conversation in aesthetic medicine, poorly healing skin wounds, orthopedics, and dental surgical reconstruction, platelet-derived growth factor (PDGF) stands as both a milestone of molecular biology andA Definitive Guide to Recognizing and Treating “Maskne”
https://practicaldermatology.com/columns/clinical-focus-1/a-definitive-guide-to-recognizing-and-treating-maskne/23520/Practical Dermatology® magazine’s resident acne columnist offers step-by-step guidance.Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Update on Atopic Dermatitis 2018
https://practicaldermatology.com/topics/general-topics/update-on-atopic-dermatitis-2018/20354/A look at the pathophysiology of AD, including structural and immunologic contributors, as well as new therapeutic developments with an eye toward breakthroughs on the horizon.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyGLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muDo You Own Real Estate in Your Practice?
https://practicaldermatology.com/topics/practice-management/do-you-own-real-estate-in-your-practice/20783/Five tips for dermatologists considering the sale of real estate to REIT.Melanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.Preparing for the Future of Teledermatology
https://practicaldermatology.com/issues/supplements/preparing-for-the-future-of-teledermatology/23475/Telehealth served as an important stopgap for medical providers and their patients in the context of the COVID-19 pandemic, but will it persist? And if so, how can you derive the most benefit?